VWM
KRYS icon

Vermillion Wealth Management’s Krystal Biotech KRYS Stock Holding History

Vermillion Wealth Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3
Closed -$775 – 2019
2026
Q1 		$775 Buy
+3
New +$798 ﹤0.01% 892

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vermillion Wealth Management's KRYS Position: Q2 2026 in Review

Vermillion Wealth Management sold out of Krystal Biotech (KRYS) in Q2 2026, closing a stake of 3 shares — an estimated $775 sold.

Vermillion Wealth Management first reported a position in KRYS in Q1 2026 and held it in 1 quarter. The position peaked at $775 in Q1 2026. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Vermillion Wealth Management reported no remaining Krystal Biotech position as of Q2 2026 after selling out during the quarter.
  • Vermillion Wealth Management sold 3 Krystal Biotech shares in Q2 2026, an estimated $775.
  • Vermillion Wealth Management first reported a position in Krystal Biotech in Q1 2026 and held it in 1 quarter.
  • Vermillion Wealth Management's Krystal Biotech position peaked at $775 in Q1 2026.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Vermillion Wealth Management's 13F filing for Q2 2026, filed 16 Jul 2026.